Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
The deadline to submit an abstract to the ASH Meeting on Hematologic Malignancies has been extended to July 8, 2015, at 11:59 p.m. (PDT).
Advance registration is now open. Hear top experts in hematologic malignancies discuss the latest developments in clinical care.
The abstract submission site is now open for the 57th ASH Annual Meeting. The deadline to submit abstracts is August 4, 2015, 11:59 p.m. (PDT).
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to medical research.
Search a database of practicing hematologists in your area.
Help move hematology forward by supporting research, career development, and quality care and education programs.
Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.
New research published online today in Blood, the Journal of the American Society of Hematology (ASH), concludes that a blood clot in an abdominal vein may be an indicator of undiagnosed cancer. The study also suggests that these clots predict poorer survival in patients with liver and pancreatic cancer.
Today Representatives Leonard Lance (R-NJ) and Brian Higgins (D-NY) and Senators Mark Kirk (R-IL) and Al Franken (D-MN) introduced the Cancer Drug Coverage Parity Act. This legislation would require private health plans with intravenous (IV) chemotherapy benefits to provide parity for orally administered and self-injectable anticancer chemotherapy medications.
Cancer patients with brain metastases who develop blood clots may safely receive blood thinners without increased risk of dangerous bleeding, according to a study published online today in Blood, the Journal of the American Society of Hematology (ASH).
The American Society of Hematology today announced the names of ten hematologists selected to participate in the third ASH Clinical Research Training Institute in Latin America (CRTI-LA). This education and mentorship program, being held April 21-22, 2015, in Cartagena, Colombia, prior to the Society’s Highlights of ASH® meeting in Latin America, is designed to prepare current hematology and hematology/oncology fellows and junior faculty working in Latin America for careers in patient-oriented clinical research.
In the first weekend of June in Chicago, representatives from medical specialty societies and state medical societies convened a meeting of the semi-annual American Medical Association (AMA)
House of Delegates. The House of Delegates is composed of more than 500 physician representatives, and they consider resolutions covering a wide gamut of issues, such as health information technology, maintenance of certification, and menu labeling for food allergies. ASH was represented at the meeting this year. Follow the link to read more.
In online comments submitted to CMS, ASH strongly supported expanding the coverage indications for the use of hematopoietic stem cell transplant for patients covered by Medicare. Under the current coverage determination, some conditions, such as myelodysplastic syndromes, are covered under a policy called Coverage with Evidence Development (CED), which allows for Medicare coverage in exchange for the provision of certain clinical data. The request that ASH supported aims to move three conditions from the category of not being named at all into the category of being covered nationwide - sickle cell disease, myelofibrosis, and lymphoma. Follow the link above to learn more.
The NIH has released a request for information soliciting input on the possible development of new policies and strategies to improve the impact and sustainability of its funded biomedical research enterprise. ASH members are encouraged to submit comments in response to this request.
On March 30, the
Centers for Medicare & Medicaid Services (CMS) issued two documents on Medicare
Part B and Part D payment for biosimilars that are relevant to hematology. On March 6, 2015, the FDA)approved filgrastim-sndz (ZARXIO Injection, Sandoz Inc.),
as a biosimilar to U.S.-licensed Neupogen, which is important to hematologic
therapy. Some of the most important
regimens for the treatment of patients with
hematologic disorders are biologic, so the release of this information is helpful for the field.
Dr. Rajkumar discusses how Dr. Robert Kyle started and developed the Multiple Myeloma Program at the Mayo Clinic. Dr. Kyle reflects on the success of the program for over 50 years.
Drs. Gale, Bennett, and Hoffman discuss factors hematologists must keep in mind when diagnosing patients with therapy-related AML or MDS, in order to prevent incorrect therapy decisions.
Drs. Badawy, Liem, and Thompson discuss several benefits, risks, and limitations of using health-related apps, focusing on hematology and oncology apps. They present a thorough study that includes recommendations of some of the best apps available, and a discussion of clinical benefits, cost-effectiveness, potential risks, and even legal concerns.
Dr. LaCasce and Dr. Weinstock discuss future challenges in lymphoma pathogenesis and advocate for lymphoma research and clinical trial participation.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology